WHAT IS **PARKY**

Parky is a Parkinson's Disease remote patient monitor.

FDA

Parky received 510(k) clearance from the USFDA. ℞

HOW IT **WORKS?**

HOW IT **WORKS?**

PATIENT

Clinician's decision making process is supported by objective data for disease management.

CLINICIAN

Reports are generated and shared with selected healthcare professional upon consent.

Patient downloads the app from iOS App Store for both iPhone and Apple Watch

℞

Apple Watch monitors motor fluctuations on the wrist and transfers data to iPhone.

PARKY APP

Patients receive medication reminders both on iPhone and Apple Watch.

Weekly and monthly med compliance data is reported based on the reminder responses.

Stories enables Parky to update and share PD related content instantly.

Steps and total recording time is reported.



Patients can view their reports in real-time.

HOW TO
LEVERAGE PARKY?

A COMPANION **TOOL**

Parky



Each Parky kit includes an iPhone, an Apple Watch and 10+ activation code cards to be distributed by the prescribing physician to the patients.

WHAT IS THE **OUTPUT?**

Parky generates patient symptom profiles, including the data types below:

- tremor
- dyskinesia
- steps
- recording time
- medication compliance

Reports are generated on a daily, weekly and monthly basis and automatically shared with the prescribing clinician.



Parky

Daily Report **Patient: Abigayle Klein** **May 03, 2023**

Legend

Tremor
Likelihood Percentage

Dyskinetic Symptom
Likelihood Percentage

Prescribed Medication Time
For Daily Medications

Clinician Guide

Total Recording Time

12 Hours 10 Minutes

Recording time is subject to patient's hardware use.

Total Steps

1432 Steps

Steps count is subject to patient's hardware use.

Medication Name	Days	Schedule and Dose			Compliance
Amantadine	Daily	07:00 AM (1)	03:00 PM (1)		100%
Rasagiline	Daily	07:00 AM (1)			100%
Pramipexole CR	Daily	07:00 AM (1)			100%
Levodopa Carbidopa ER	Daily	10:00 PM (1)			100%
Levodopa Carbidopa Entacapone	Daily	07:00 AM (1) 07:00 PM (1)	11:00 AM (1) 10:00 PM (1)	03:00 PM (1)	100%



Parky 20.06.2022

Medication Schedule

Name	Time	Days	Dosage
Epamor 20mg	10am, 12pm, 2pm, 5pm	Everyday	2
Gepamor 20mg	1pm	Mon.Thu. Sun.	1

Medication schedule is subject to patient input.

How to Interpret The Reports?

This is a stacked bar chart that shows probabilities of tremor and dyskinesia. Each stack represents a 15-minute window.
Presence of any symptom probability does not rule out others.

On daily reports data is shown for each hour divided into 15 minutes.
On weekly reports the average of same hours across past 7 days are displayed.
On monthly reports the average of same hours across 30 days are displayed.



FROM SNAPSHOT **TO HIGH RESOLUTION**

For research purposes, Parky can generate tailor-made reports based on collected raw data on tremor and dyskinesia episodes, mobility, and symptom correlation with medication compliance.

RESEARCH

Parky is build upon Movement Disorders API developed by Apple Inc.

SCIENCE TRANSLATIONAL MEDICINE | RESEARCH ARTICLE

BIOSENSORS

Smartwatch inertial sensors continuously monitor real-world motor fluctuations in Parkinson's disease

Rob Powers[1], Maryam Etezadi-Amoli[1], Edith M. Arnold[1], Sara Kianian[1,2], Irida Mance[1], Maxsim Gibiansky[1], Dan Trietsch[1], Alexander Singh Alvarado[1], James D. Kretlow[1], Todd M. Herrington[3,4], Salima Brillman[5], Nengchun Huang[6], Peter T. Lin[6], Hung A. Pham[1], Adeeti V. Ullal[1]*

Longitudinal, remote monitoring of motor symptoms in Parkinson's disease (PD) could enable more precise treatment decisions. We developed the Motor fluctuations Monitor for Parkinson's Disease (MM4PD), an ambulatory monitoring system that used smartwatch inertial sensors to continuously track fluctuations in resting tremor and dyskinesia. We designed and validated MM4PD in 343 participants with PD, including a longitudinal study of up to 6 months in a 225-subject cohort. MM4PD measurements correlated to clinical evaluations of tremor severity ($\rho = 0.80$) and mapped to expert ratings of dyskinesia presence ($P < 0.001$) during in-clinic tasks. MM4PD captured symptom changes in response to treatment that matched the clinician's expectations in 94% of evaluated subjects. In the remaining 6% of cases, symptom data from MM4PD identified opportunities to make improvements in pharmacologic strategy. These results demonstrate the promise of MM4PD as a tool to support patient-clinician communication, medication titration, and clinical trial design.

Apple conducted a clinical study for design and development of the algorithms for tremor and dyskinesia detection.

The study is known to be the largest in the field of PD wearables in terms of participant numbers and follow-up time.

List of clinical investigators:

- Salima Brillman, MD
  Parkinson's Disease and Movement Center of Silicon Valley, Menlo Park, CA 94025, USA

- Todd M. Herrington, MD
  Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA
  Department of Neurology, Harvard Medical School, Boston, MA 02115, USA

- Nengchun Huang, MD
  Silicon Valley Parkinson's Center, Los Gatos, CA 95032, USA

BENEFITS

Less time spent for disease management and decision making

HCP

Better treatment titration

Objective Data

Increased medication adherence



PATIENT

Increased quality of life

WE **ARE h2o°** therapeutics

h2o is a digital therapeutics developer with a focus on wearable technologies. By the use of AI, AR, and mobile technologies, we make real-time human data become a handy tool for disease management in certain therapeutic areas. Our core understanding of digital therapeutics lies in the power of AI, the robustness of their clinical health research, and high levels of user engagement.

Parky

FDA 510(K)
Cleared

Foggy

Clinical Research
Phase II

covie

FDA BDD
Under Review

THANK YOU!

h2o° therapeutics | Parky